Maximizing Outcomes: The Impact of Oral Medications on Weight Management
Tracking # 20-1298518
Course overview
Oral anti-obesity medications (AOMs) serve as valuable tools in the management of obesity. Current guidelines advocate for a multimodal approach to obesity treatment, incorporating lifestyle interventions such as diet and exercise alongside pharmacotherapy when appropriate. The decision to initiate an oral AOM should be personalized, considering the weight loss goals, the comorbidities of the patient, and the safety profile of the medication. This educational activity will provide an in-depth review of the mechanisms of action, dosing strategies, and the efficacy and safety profiles of oral AOMs. Additionally, this activity will emphasize the critical role of long-term monitoring, shared decision-making, and interprofessional collaboration in ensuring these therapies are used safely and effectively to optimize patient outcomes.
Subject areas
This course counts toward the state boards and subject areas below.
Florida Board of Pharmacy
Registered Pharmacy Technician
Michigan Board of Pharmacy
Pharmacy Technician
Disclosure statements
The following individuals were involved in developing this activity: L. Austin Fredrickson, MD, FACP, Liz Fredrickson, PharmD, BCPS, Susan Bowlin, DNP, FNP-BC, ACNP-BC, CBN, and Pamela Sardo, PharmD, BS. Austin Frederickson, Liz Frederickson, and Pamela Sardo have no conflict of interest or financial relationship or commercial or financial support relevant to this activity to report or disclose in the development of this activity. Susan Bowlin is a member of the Speaker’s Bureau for Eli Lilly and Novo Nordisk. Any potential conflicts of interest were mitigated.